{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T15:26:22Z","timestamp":1785338782675,"version":"3.55.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T00:00:00Z","timestamp":1647302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>We studied the distribution and <jats:italic>in vitro<\/jats:italic> pathogenicity of anti-DSG3 IgG subclasses during the course of pemphigus vulgaris (PV).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We longitudinally studied the distribution of anti-DSG3 IgG subclasses (before <jats:italic>versus<\/jats:italic> after treatment) in sera from PV patients, using an addressable-laser bead immunoassay (ALBIA). The <jats:italic>in vitro<\/jats:italic> pathogenicity of corresponding sera was tested using keratinocyte dissociation and immunofluorescence assays.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Sixty-five sera were assessed at baseline (33 from patients treated with rituximab and 32 with corticosteroids). Sixty-three percent of these baseline sera contained 2 or more anti-DSG3 IgG subclasses <jats:italic>versus<\/jats:italic> 35.7% of sera from patients in complete remission (CR) and 75.0% of sera from patients with persistent disease activity after treatment. IgG4 was the most frequently detected anti-DSG3 IgG subclass, both in patients with disease activity and in those in CR. The presence of three or more anti-DSG3 IgG subclasses was predictive of relapse, in particular when it included IgG3, with a positive predictive value of 62.5% and a negative predictive value of 92%. While anti-DSG3 IgG4 Abs from sera collected before treatment were most often pathogenic, anti-DSG3 IgG4 from sera collected after treatment were pathogenic only after adjusting their titer to the one measured before treatment. The IgG3 fraction containing anti-DSG3 Abs also had an <jats:italic>in vitro<\/jats:italic> pathogenic effect. The disappearance of the pathogenic effect of some sera after removal of anti-DSG3 IgG3 suggested an additional effect of this IgG subclass.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The serum levels and number of anti-DSG3 IgG subclasses drive the pathogenic effect of pemphigus sera and may predict the occurrence of relapses.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.849790","type":"journal-article","created":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T11:46:26Z","timestamp":1647344786000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["The Diversity of Serum Anti-DSG3 IgG Subclasses Has a Major Impact on Pemphigus Activity and Is Predictive of Relapses After Treatment With Rituximab"],"prefix":"10.3389","volume":"13","author":[{"given":"Marie-Laure","family":"Golinski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Lemieux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maud","family":"Maho-Vaillant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Barray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Drouot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Schapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Petit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hertl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Calbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Joly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivien","family":"H\u00e9bert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"90\u22126","DOI":"10.1006\/clin.1997.4408","article-title":"Mechanisms of Acantholysis in Pemphigus Vulgaris: Role of IgG Valence","volume":"85","author":"Mascar\u00f3","year":"1997","journal-title":"Clin Immunol Immunopathol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.701809","article-title":"Autoantibody-Specific Signalling in Pemphigus","volume":"8","author":"Schmitt","year":"2021","journal-title":"Front Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"775\u221280","DOI":"10.1046\/j.1365-2133.2001.04132.x","article-title":"The Severity of Cutaneous and Oral Pemphigus Is Related to Desmoglein 1 and 3 Antibody Levels","volume":"144","author":"Harman","year":"2001","journal-title":"Br J Dermatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"142\u22129","DOI":"10.1111\/bjd.14405","article-title":"Calculation of Cut-Off Values Based on the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) and Pemphigus Disease Area Index (PDAI) Pemphigus Scoring Systems for Defining Moderate, Significant and Extensive Types of Pemphigus","volume":"175","author":"Boulard","year":"2016","journal-title":"Br J Dermatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"31\u22127","DOI":"10.1016\/j.jid.2018.04.042","article-title":"Large International Validation of ABSIS and PDAI Pemphigus Severity Scores","volume":"139","author":"H\u00e9bert","year":"2019","journal-title":"J Invest Dermatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"529\u221235","DOI":"10.1001\/archdermatol.2009.9","article-title":"ELISA Testing of Anti-Desmoglein 1 and 3 Antibodies in the Management of Pemphigus","volume":"145","author":"Abasq","year":"2009","journal-title":"Arch Dermatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2021.09.013","article-title":"Temporal Outcomes After Rituximab Therapy for Pemphigus Vulgaris","author":"Tovanabutra","year":"2021","journal-title":"J Invest Dermatol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"85\u22129","DOI":"10.1159\/000246938","article-title":"Correlation of Subclasses of IgG With Disease Activity in Pemphigus Vulgaris","volume":"189","author":"Bhol","year":"1994","journal-title":"Dermatology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"337\u221242","DOI":"10.1046\/j.1365-2133.2000.03659.x","article-title":"The Distribution of Pemphigus Vulgaris-IgG Subclasses and Their Reactivity With Desmoglein 3 and 1 in Pemphigus Patients and Their First-Degree Relatives","volume":"143","author":"Kricheli","year":"2000","journal-title":"Br J Dermatol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.celrep.2019.06.066","article-title":"Single-Cell Analysis Suggests That Ongoing Affinity Maturation Drives the Emergence of Pemphigus Vulgaris Autoimmune Disease","volume":"28","author":"Cho","year":"2019","journal-title":"Cell Rep"},{"key":"B11","doi-asserted-by":"publisher","first-page":"545\u221252","DOI":"10.1001\/jamadermatol.2020.0290","article-title":"Factors Associated With Short-Term Relapse in Patients With Pemphigus Who Receive Rituximab as First-Line Therapy: A Post Hoc Analysis of a Randomized Clinical Trial","volume":"156","author":"Mignard","year":"2020","journal-title":"JAMA Dermatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"307\u221211","DOI":"10.1002\/jcla.1860030509","article-title":"Comparison of Igg Subclasses and Complement Binding Activity of Autoantibodies From Patients With Bullous Pemphigoid and Pemphigus","volume":"3","author":"Brooks","year":"1989","journal-title":"J Clin Lab Anal"},{"key":"B13","doi-asserted-by":"publisher","first-page":"787\u221290","DOI":"10.1001\/archderm.1989.01670180059006","article-title":"Determination of IgG Subclasses in Patients With Pemphigus With Active Disease and in Remission","volume":"125","author":"David","year":"1989","journal-title":"Arch Dermatol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"585\u22127","DOI":"10.1111\/1523-1747.ep12709613","article-title":"IgG Subclasses of Intercellular and Basement Membrane Zone Antibodies: The Relationship to the Capability of Complement Fixation","volume":"92","author":"Yamada","year":"1989","journal-title":"J Invest Dermatol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"43\u22129","DOI":"10.1007\/BF00915155","article-title":"Subclass Distribution of Human IgG Autoantibodies in Pemphigus","volume":"8","author":"Jones","year":"1988","journal-title":"J Clin Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"55\u221261","DOI":"10.1016\/S0923-1811(00)00158-4","article-title":"Predominant IgG4 Subclass in Autoantibodies of Pemphigus Vulgaris and Foliaceus","volume":"26","author":"Futei","year":"2001","journal-title":"J Dermatol Sci"},{"key":"B17","doi-asserted-by":"publisher","first-page":"661\u22127","DOI":"10.1084\/jem.178.2.661","article-title":"Structural Features of Human Immunoglobulin G That Determine Isotype-Specific Differences in Complement Activation","volume":"178","author":"Tao","year":"1993","journal-title":"J Exp Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1463\u22129","DOI":"10.1056\/NEJM198906013202206","article-title":"The Pathogenic Effect of IgG4 Autoantibodies in Endemic Pemphigus Foliaceus (Fogo Selvagem)","volume":"320","author":"Rock","year":"1989","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1245\u221253","DOI":"10.1111\/j.1365-2133.2012.11144.x","article-title":"Enrichment of Total Serum IgG4 in Patients With Pemphigus","volume":"167","author":"Funakoshi","year":"2012","journal-title":"Br J Dermatol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0156800","article-title":"Pathogenicity and Epitope Characteristics Do Not Differ in IgG Subclass-Switched Anti-Desmoglein 3 IgG1 and IgG4 Autoantibodies in Pemphigus Vulgaris","volume":"11","author":"Lo","year":"2016","journal-title":"PloS One"},{"key":"B21","doi-asserted-by":"publisher","first-page":"241\u22122","DOI":"10.1111\/j.1468-3083.2004.00708.x","article-title":"IgG4 as the Predominant Autoantibody in Sera From Patients With Active State of Pemphigus Vulgaris","volume":"18","author":"Ayatollahi","year":"2004","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1183\u22128","DOI":"10.1046\/j.1365-2133.2001.04228.x","article-title":"IgG, IgA and IgE Autoantibodies Against the Ectodomain of Desmoglein 3 in Active Pemphigus Vulgaris","volume":"144","author":"Spaeth","year":"2001","journal-title":"Br J Dermatol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"516\u22122","DOI":"10.3109\/08916934.2012.702811","article-title":"Specific Immunoglobulin Isotypes Correlate With Disease Activity, Morphology, Duration and HLA Association in Pemphigus Vulgaris","volume":"45","author":"Dhandha","year":"2012","journal-title":"Autoimmunity"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2031\u221240","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-Line Rituximab Combined With Short-Term Prednisone Versus Prednisone Alone for the Treatment of Pemphigus (Ritux 3): A Prospective, Multicentre, Parallel-Group, Open-Label Randomised Trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet Lond Engl"},{"key":"B25","doi-asserted-by":"publisher","first-page":"4520\u22128","DOI":"10.1074\/jbc.RA118.006743","article-title":"Synergy Among non-Desmoglein Antibodies Contributes to the Immunopathology of Desmoglein Antibody-Negative Pemphigus Vulgaris","volume":"294","author":"Chernyavsky","year":"2019","journal-title":"J Biol Chem"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01190","article-title":"Non-Desmoglein Antibodies in Patients With Pemphigus Vulgaris","volume":"9","author":"Amber","year":"2018","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"3781\u221290","DOI":"10.1172\/JCI64413","article-title":"Pemphigus Autoantibodies Generated Through Somatic Mutations Target the Desmoglein-3 Cis-Interface","volume":"122","author":"Di Zenzo","year":"2012","journal-title":"J Clin Invest"},{"key":"B28","doi-asserted-by":"publisher","first-page":"35\u221243","DOI":"10.1111\/j.1600-0625.2007.00615.x","article-title":"IgG Against Extracellular Subdomains of Desmoglein 3 Relates to Clinical Phenotype of Pemphigus Vulgaris","volume":"17","author":"M\u00fcller","year":"2008","journal-title":"Exp Dermatol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"321950","DOI":"10.1155\/2010\/321950","article-title":"Targeted Immunotherapy With Rituximab Leads to a Transient Alteration of the IgG Autoantibody Profile in Pemphigus Vulgaris","volume":"2010","author":"M\u00fcller","year":"2010","journal-title":"Dermatol Res Pract"},{"key":"B30","doi-asserted-by":"publisher","first-page":"271\u22128","DOI":"10.1111\/jdv.17770","article-title":"Analysis of Clinical Characteristics, Prognosis and Antibody Pathogenicity of Pemphigus Patients Positive for Anti-Desmoglein IgG Autoantibodies in Remission: A Retrospective Cohort Study","volume":"36","author":"Zhao","year":"2021","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2021.01.031","article-title":"Rituximab and Corticosteroid Effect on Desmoglein-Specific B Cells and Desmoglein-Specific T Follicular Helper Cells in Pemphigus","volume":"141","author":"Maho-Vaillant","year":"2021","journal-title":"J Invest Dermatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.849790\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T11:46:29Z","timestamp":1647344789000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.849790\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,15]]},"references-count":31,"alternative-id":["10.3389\/fimmu.2022.849790"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.849790","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,15]]},"article-number":"849790"}}